Current Cardiology Reports

, Volume 14, Issue 4, pp 433–442 | Cite as

Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists in Atherosclerosis Prevention

Ischemic Heart Disease (S Brener, Section Editor)


Atherosclerosis is a highly complex biological process that has become the scourge of modern civilization. Endothelial dysfunction is the first step in the development of atherosclerosis. The renin-angiotensin-aldosterone system (RAAS) plays an important role in the development of endothelial dysfunction and atherosclerosis. Several studies have shown that in vitro blockade of the RAAS is associated with improvement in markers of endothelial dysfunction and inflammation. Many clinical trials have demonstrated a clear benefit of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) manifested by a reduction of cardiovascular events. These findings suggest that ACEIs and ARBs can play an important role in prevention of atherosclerosis and in the delay of its progression. In this review we focus on the importance of RAAS blockade to prevent or delay progression of atherosclerosis and its impact on reduction of cardiovascular events.


Atherosclerosis Renin-angiotensin-aldosterone-system Angiotensin-converting enzyme inhibitors Angiotensin receptor blockers Prevention 



No potential conflicts of interest relevant to this article were reported.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Lonn E. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Curr Atheroscler Rep. 2002;4(5):363–72.PubMedCrossRefGoogle Scholar
  2. 2.
    •• Ferrario C. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Vasc Health Risk Manag. 2009;5(1):301–14. This is a complete review regarding effects of ARBs on atherosclerosis prevention. It also gives a great explanation of the pathophysiology of RAAS and atherosclerosis.PubMedCrossRefGoogle Scholar
  3. 3.
    • Vijayaraghavan K, Deedwania P. Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention. Cardiol Clin. 2011;29(1):137–56. This article gives a complete explanation of the role of RAAS in atherosclerosis.PubMedCrossRefGoogle Scholar
  4. 4.
    Virmani R, Robinowitz M, Geer JC, et al. Coronary artery atherosclerosis revisited in Korean war combat casualties. Arch Pathol Lab Med. 1987;111(10):972–6.PubMedGoogle Scholar
  5. 5.
    •• Shahin Y, Khan JA, Samuel N, Chetter I. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomized controlled trials. Atherosclerosis. 2011;216(1):7–16. This meta-analysis shows the effect of ACEIs on endothelial dysfunction, which is the first step for atherosclerosis.PubMedCrossRefGoogle Scholar
  6. 6.
    Dzau VJ. Tissue angiotensin and pathobiology of vascular disease-a unifying hypothesis. Hypertension. 2001;37(4):1047–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Dzau VJ, Bernstein K, Celermejer D, et al. The relevance of tissue angiotensin-converting enzyme; manifestations in mechanistic and endpoint dat. Am J Cardiol. 2001;88(9A):1L–20L.PubMedCrossRefGoogle Scholar
  8. 8.
    McDonald KM, Mock J, D’Aloia A, et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation. 1995;91(7):2043–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996;94(11):2756–67.PubMedCrossRefGoogle Scholar
  10. 10.
    Wassmann S, Czech T, van Eickels M, et al. Inhibition of diet induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double knockout mice. Circulation. 2004;110(19):3062–7.PubMedCrossRefGoogle Scholar
  11. 11.
    • Fukuda D, Enomoto S, Nagai R, Sata M. Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. Biomed pharmacother. 2009;63(10):754–61. This article demonstrate the effect of RAAS in vascular infiltration by macrophages and the possibility that inhibition of RAAS will lead to not just prevention but reduction of atherosclerotic lesion.PubMedCrossRefGoogle Scholar
  12. 12.
    Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet induced hypercholesterolemia. Circulation. 2000;101(13):1586–93.PubMedCrossRefGoogle Scholar
  13. 13.
    Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15 suppl 5:S65–72.PubMedGoogle Scholar
  14. 14.
    Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15(3):327–31.PubMedCrossRefGoogle Scholar
  15. 15.
    Hoshida S, Nishida M, Yamashita N, et al. Vascular angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Atherosclerosis. 1997;130(1–2):53–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Rolland PH, Carpiot P, Friggi A, et al. Effects of angiotensin-converting enzyme inhibition with perindopril on hemodynamics, arterial structure and wall rheology in the hindquarters of atherosclerosis mini-pigs. Am J Cardiol. 1993;71(17):22E–7E.PubMedCrossRefGoogle Scholar
  17. 17.
    Powell JS, Clozel JP, Müller RK, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245(4914):186–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Yusuf S, Sleight P, Pogue J, Bosch J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342(3):145–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double blind, placebo controlled, multicenter trial (the EUROPA study). Lancet. 2003;362(9386):782–8.PubMedCrossRefGoogle Scholar
  20. 20.
    PROGRESS collaborative group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet. 2001;358(9287):1033–41.CrossRefGoogle Scholar
  21. 21.
    Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood pressure lowering arm (ASCOT-BPLA) a multicentre randomized controlled trial. Lancet. 2005;366(9489):895–906.PubMedCrossRefGoogle Scholar
  22. 22.
    Ahimastos AA, Lawler A, Reid CM, et al. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med. 2006;144(9):660–4.PubMedGoogle Scholar
  23. 23.
    Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058–68.PubMedCrossRefGoogle Scholar
  24. 24.
    Nakamura M, Funakoshi T, Arakawa N, et al. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure. J Am Coll Cardiol. 1994;24(5):1321–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Millgárd J, Hägg A, Sarabi M, Lind L. Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients. J Hum Hypertens. 1998;12(8):511–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Mühlen BV, Millgård J, Lind L. Effects of digoxin, furosemide, enalaprilat and metoprolol on endothelial function in young normotensive subjects. Clin Exp Pharmacol Physiol. 2001;28(5–6):381–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (trial on Reversing Endothelial Dysfunction) study. Circulation. 1996;94(3):258–65.PubMedCrossRefGoogle Scholar
  28. 28.
    Kovacs I, Toth J, Tarjan J, Koller A. Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE. Eur J Heart fail. 2006;8(5):451–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Hermann TS, Li W, Dominguez H, et al. Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J CLin End Metab. 2006;91(3):1001–8.CrossRefGoogle Scholar
  30. 30.
    Girerd X, Giannattasio C, Moulin C, et al. Regression of radial artery wall hypertrhophy and improvement of carotid artery compliance after long term antihypertensive treatment in elderly patients. J Am Coll Cardiol. 1998;31(5):1064–73.PubMedCrossRefGoogle Scholar
  31. 31.
    Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006;48(1):80–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Joannides R, Bizet-Nafeh C, Costentin A, et al. Chronic ACE inhibitors enhances the endothelial control of arterial mechanisms and flow-dependent vasodilatation in heart failure. Hypertension. 2001;38(6):1446–50.PubMedCrossRefGoogle Scholar
  33. 33.
    Yavuz D, Koς M, Toprak A, et al. Effects of ACE inhibition and AT-1 receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin Angiotensin Aldosterone syst. 2003;4(3):197–203.PubMedCrossRefGoogle Scholar
  34. 34.
    Watanabe S, Tagawa T, Yamakawa K, et al. Inhibition of the renin-angiotensin system prevents free fatty acid induced acute endothelial dysfunction in humans. Arterioscler thromb Vasc Biol. 2005;25(11):2376–80.PubMedCrossRefGoogle Scholar
  35. 35.
    Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases human vascular tissue type plasminogen activator release through endogenous bradykinin. Circulation. 2003;107(4):579–85.PubMedCrossRefGoogle Scholar
  36. 36.
    Mullens MJ, Clarkson P, Donald AE, et al. Effect of enalapril on endothelial function in young insulin dependent diabetic patients: a randomized double blind study. J Am Coll Cardiol. 1998;31(6):1330–5.CrossRefGoogle Scholar
  37. 37.
    Cashin-Hemphill L, Holmvang G, Chan RC, et al. Angiotensin converting enzyme inhibition as anti-atherosclerotic therapy: an answer yet. Quinapril ischemic event trial. Am J Cardiol. 1999;83(1):43–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Bots ML, Remme WJ, Lüscher TF, EUROPA-PERFECT Investigators, et al. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc, Drug Ther. 2007;21(4):269–79.CrossRefGoogle Scholar
  39. 39.
    Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007;73(1):237–46.PubMedCrossRefGoogle Scholar
  40. 40.
    Fleming I, Kohlstedt K, Busse R. The Tissue renin-angiotensin system and intracellular signaling. Curr Opin Nephrol Hypertens. 2006;15:8–13.PubMedCrossRefGoogle Scholar
  41. 41.
    Lazar HL, Bao Y, Rivers S, Colton T, Bernard SA. High tissue affinity angiotensin-converting enzyme inhibitors improve endothelial function and reduce infarct size. Ann Thorac Surg. 2001;72(2):548–53.PubMedCrossRefGoogle Scholar
  42. 42.
    Ruzicka M, Coletta E, White R, et al. Effects of ACE inhibitors on cardiac angiotensin II and aldosterone in humans: “Relevance of lipophilicity and affinity for ACE”. Am J Hypertens. 2010;23(11):1179–82.PubMedCrossRefGoogle Scholar
  43. 43.
    Jorde UP, Vittorio TJ, DImayuga CA, et al. Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure. Am J Cardiol. 2004;94(12):1501–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Yusuf S, Teo KK, Pogue J, et al. ONTARGET investigators: telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.PubMedCrossRefGoogle Scholar
  45. 45.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med. 2003;349(20):1893–906.PubMedCrossRefGoogle Scholar
  46. 46.
    Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE study group: cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359(9311):995–1003.PubMedCrossRefGoogle Scholar
  47. 47.
    Rizzoni D, Porteri E, De Ciuceis C, et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension. 2005;45(4):659–65.PubMedCrossRefGoogle Scholar
  48. 48.
    Koh KK, Quon MJ, Lee Y, et al. Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. Eur Heart J. 2007;28(12):1440–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Schmieder RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes care. 2007;30(6):1351–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Koh KK, Quon MJ, Han SH, et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol. 2010;140(1):73–81.PubMedCrossRefGoogle Scholar
  51. 51.
    • Toyama K, Nakamura T, Kataoka K, et al. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferation activated receptor-γ-dependent activity. Biochem Biophys Res Commun. 2011;410(3):508–13. This article showed an additional effect of RAAS inhibition in diabetes mellitus patients beyond the renal protection.PubMedCrossRefGoogle Scholar
  52. 52.
    Pellicia F, Pasceri V, Cianfrocca C, et al. Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebo controlled study. Atherosclerosis. 2010;210(2):510–5.CrossRefGoogle Scholar
  53. 53.
    • Zankl AR, Ivandic B, Andrassy M, et al. Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease. Clin Res Cardiol. 2010;99(12):787–94. This randomized, placebo-controlled, double-blind trial showed improvement in symptoms in peripheral vascular disease, with a greater magnitude than the one reported by other therapies.PubMedCrossRefGoogle Scholar
  54. 54.
    Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by angiotensin receptor antagonist losartan. Circulation. 2000;101(14):1653–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Olsen MH, Watchell K, Neland K, et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood press. 2005;14(3):177–83.PubMedCrossRefGoogle Scholar
  56. 56.
    Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65(3):1041–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Fliser D, Buchholz K, Haller H. European trial on Olmesartan and pravastatin in inflammation and atherosclerosis (EUTOPIA) investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110(9):1103–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Hackam DG, Sultan NM, Criqui MH. Vascular protection in peripheral artery disease: systematic review and modeling study. Heart. 2009;95(13):1098–102.PubMedCrossRefGoogle Scholar
  59. 59.
    •• Koh KK, Han SH, Oh PC, et al. Combination therapy for treatment or prevention of atherosclerosis: Focus on the lipid-RAAS interaction. Atherosclerosis. 2010;209(2):307–13. The article provides useful information and explanation of possible effects of combination therapy in atherosclerosis prevention.PubMedCrossRefGoogle Scholar
  60. 60.
    Li Z, Iwai M, Wu L, et al. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension. 2004;44(5):758–63.PubMedCrossRefGoogle Scholar
  61. 61.
    Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004;110(24):3687–92.PubMedCrossRefGoogle Scholar
  62. 62.
    Koh KK, Quon MJ, Han SH, et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension. 2005;45(6):1088–93.PubMedCrossRefGoogle Scholar
  63. 63.
    Koh KK, Quon MJ, Han SH, et al. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. Atherosclerosis. 2007;194(1):230–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Ceriello A, Assaloni R, Da Ros R, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress and inflammation in type 2 diabetic patients. Circulation. 2005;111(19):2518–24.PubMedCrossRefGoogle Scholar
  65. 65.
    Messerli FH, Yuzefpolskaya M. Q: is an ACE inhibitor plus an ARB more effective than either drug alone? Cleve Clin J Med. 2009;76(12):693–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Messerli FH. The sudden demise of dual renin-angiotensin system blockade of the soft science of the surrogate end point. J Am Coll Cardiol. 2009;53(6):468–70.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of Cardiovascular Medicine, Lillehei Heart InstituteUniversity of Minnesota Medical CenterMinneapolisUSA

Personalised recommendations